Mammazentrum Hamburg MVZ GbR
Hospital
Location:
Hamburg,
Germany (DE)
ISNI: -
Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials (2019)
Jank P, Loibl S, Fasching P, Karn T, Marme F, Mueller V, Schem C, et al.
Conference contribution
Mutational diversity and therapy response in breast cancer-a sequencing analysis in the neoadjuvant GeparSepto trial (2018)
Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, et al.
Conference contribution
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial (2018)
Stevic I, Mueller V, Weber K, Fasching P, Karn T, Marme F, Schem C, et al.
Journal article
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto (2018)
Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching P, Lederer B, et al.
Journal article